NuvaRing Attorneys Report That Patients May Be Injured
NuvaRing Birth Control Enhances Stroke Risk, Cardiovascular Problems
Thousands of women have reportedly suffered from heart attacks, strokes, and fatalities as a result of side effects of NuvaRing birth control device. The venous thromboembolic events caused by blood clots attributed to the hormonal contraceptive adverse events result in pulmonary embolism and deep vein thrombosis, leading to hospitalization, long-term treatment, or death. More than 1,500 NuvaRing lawsuits seeking compensatory and punitive damages await trial in various state and federal courts. The number of product liability litigants is set to rise, as more people are consulting lawyers to initiate litigations against manufacturer Merck for endangering their health for commercial gains.
NuvaRing Cardiovascular Risks
Third generation hormonal contraceptive NuvaRing contains progestin along with etonogestrel, which is an active substance derived from prodrug desogestrel. Researchers have discovered that desogestrel can double the risk of blood clots. Known as venous thrombosis in medical annals, these clots often travel from legs to other parts of the body and block blood vessels. People with thromboembolic events are at a greater risk of strokes, breathing difficulty due to lung artery block, visionary problems caused by eye artery blockages, and other complications.
The most reported cardiovascular risks caused by NuvaRing blood clot side effects include:
Death because of prolonged stroke or mayocardial infraction.
Heart attack or mayocardial infraction following blockage of blood supply to the heart. Blood clots interrupt or prevent blood supply to heart muscle and cells, which leads to their death and hinders functioning of the heart.
Heightened ischemic events results in restricted blood supply caused by occlusion of coronary artery. This creates oxygen shortage, leading to near fatal conditions.
Stroke occurs when blood clots block vessels carrying blood and oxygen from heart to brain. A medical emergency, it can lead to sudden death.
Pulmonary embolism caused by the blockage of artery supplying blood to the lung. Blood clots caused by NuvaRing side effects in the legs often break off and reach the lung and choke the blood and oxygen supply. Chest pain and palpitations are prominent symptoms.
Deep vein thrombosis or blood clots in the deep vein of the legs are the most frequent NuvaRing side effect. These clots often migrate to different areas and create arterial blockages.
NuvaRing Heart Attack, Stroke Studies
- In October 2011, a research report endorsed and made public by the FDA cautioned about the higher possibility of heart attacks and strokes because of “third generation” progestin hormone used in NuvaRing. Researchers went through more than 800,000 medical records of women and discovered that the contraceptive vaginal ring poses 56 percent higher chances of blood clotting and consequent venous thromboembolic events, including stroke and heart attack.
- According to Danish researchers working on the efficacy of NuvaRing and similar hormonal contraceptives, women using NuvaRing are two to six times more prone to ischemic events and myocardial infarction. Published in the British Medical Journal in May 2012, the findings derived from the study of more than 1.5 million medical records showed that incidences of thrombosis, stroke, and heart attack are 6.5 times higher for those using NuvaRing compared to other contraceptive users. When compared to single-hormone contraceptives, NuvaRing enhances the risks by two to three times.
Side Effects
Some women who have had NuvaRing implanted experienced serious and even debilitating or life-threatening side-effects. Serious side effects that have been linked to NuvaRing include:
- Blood clots
- Cerebral thrombosis
- Deep vein thrombosis (DVT)
- Heart attack or myocardial infarction (MI)
- Pulmonary embolism
- Retinal thrombosis
- Stroke or cerebral hemorrhage
- Thrombophlebitis and venous thrombosis with or without embolism
- Toxic shock syndrome (TSS)
If you experienced adverse NuvaRing side effects or have a loved one who suffered injury following the implantation of NuvaRing, you may have a potential NuvaRing lawsuit.
More Information
Approved by the Food and Drug Administration (FDA) in 2001, NuvaRing is a non-biodegradable, latex-free, flexible vaginal ring containing a combination of the hormones estrogen (ethinyl estradiol) and progestin (etonogestrel). Etonogestrel is the active metabolite of desogestrel, a synthetic form of the naturally occurring female sex hormone progesterone. The NuvaRing contraceptive ring is designed to prevent pregnancy by releasing a steady dose of the hormone combination into the bloodstream through the vaginal walls over the course of 21 days. The hormones prevent ovulation, change the cervical mucus to prevent sperm penetration, and thin the lining of the uterus to, theoretically, prevent sperm implantation.
In October 2003, The New England Journal of Medicine addressed research suggesting that, when taken orally, desogestrel can significantly increase the risk of blood clots. If left untreated, such blood clots can develop into more serious conditions that may include stroke, heart attack, pulmonary embolism, or deep vein thrombosis. These findings, as well as those from other studies, were based upon analysis of the effect of oral contraceptives containing desogestrel.
A Swiss report was released in June 2010 which claimed there were approximately 40 deaths reported in the FDA database of adverse events associated with Nuvaring. The current label and package insert for NuvaRing refers only to studies conducted on women using combination oral contraceptives and suggests that adverse reactions associated with the use of combination hormonal oral contraceptives are likely to apply to combination vaginal contraceptives like NuvaRing. The label, however, states that there is no available epidemiologic data to determine whether the safety and efficacy of vaginal administration of combination hormonal contraceptives differs from oral administration. To date, there is no comprehensive study of NuvaRing and the long-term health effects of its vaginally delivered combination.
Our team of attorneys are now investigating claims and prepared to file NuvaRing lawsuits involving the vaginal ring contraceptive medication NuvaRing®. NuvaRing is manufactured by New Jersey-based Organon USA, Inc., a company that Schering-Plough Corporation acquired in 2007, and has been linked to serious events such as blood clots, pulmonary embolism, stroke and heart attack.Call us today at 1-800-632-1404 for a FREE CONSULTATION.
No Recovery, No Fee
We take NuvaRing litigation cases on a contingency basis. That means that there is no cost to you unless we and our co-counsel are able to recover a settlement or judgment on your behalf. So, unless your case is resolved by trial, arbitration, settlement, or other resolution, you do not have to pay any attorney fees to us, or pay any costs. Litigation costs include filing fees, court reporter fees for deposition, copying costs, experts, and travel. Litigation costs are paid by our firm so you don’t have to have cash to pursue justice against medical device corporations.
About us
Our team of attorneys have been retained by clients across the world as to allegedly defective and improperly designed medical devices and prescription drugs. In fact, our team of attorneys has represented patients around the globe for the allegedly defective Advanced Bionics HiRes90k cochlear implant device and other medical devices including the DePuy hip implant, the Mirena IUD and the transvaginal mesh and transvaginal sling devices including from C.R. Bard, AMS, Boston Scientific and Johnson & Johnson’s Ethicon.
As a NuvaRing attorney, we will investigate your claim and with our co-counsel we stand ready to push your case ahead.
FOR A FREE CASE EVALUATION:
CALL TOLL FREE: (800) 632-1404
EMAIL: clicking here.
FILL OUT THIS FORM FOR FREE HELP:
NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.